2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2182 CD70 as an independent biomarker and therapeutic target for computationally optimized virus-free CRISPR knock-in CAR-T cells in high-risk myeloma

Bonell Patino-Escobar, MD, Daniel D Waller, PhD2, Corynn Kasap, MD, PhD3, Amrik S Kang, PhD4, Sham Rampersaud, BS5, Ke Li, PhD6, Radhika Dalal, BS7, Xinyu Chen8, Daniela Ordoñez9, Hua Li, PhD10, Paul Phojanakong, BA11, Juan Antonio Camara-Serrano, PhD12, Yan Zeng, MD13, Veronica Steri, PhD14, Tanja Kortemme, PhD15, Justin Eyquem, PhD16, Brian Shy, MD, PhD17, Arun Wiita, MD, PhD18
1 University of California, San Francisco, San Francisco, California, United States
2 University of California, San Francisco, San Francisco, California, United States
3 University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
4 University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
5 University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
6 University of California, San Francisco, San Francisco, California, United States
7 University of California, San Francisco, San Francisco, California, United States
8 University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
9 City College of San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
10 University of California, San Francisco, San Francisco, California, United States
11 University of California, San Francisco, San Francisco, California, United States
12 University of California, San Francisco, San Francisco, California, United States
13 University of California, San Francisco, San Francisco, California, United States
14 University of California, San Francisco, San Francisco, California, United States
15 Chan Zuckerberg Biohub, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
16 University of California, San Francisco, San Francisco, California, United States
17 University of California, San Francisco, San Francisco, California, United States
18 Chan Zuckerberg Biohub, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States

Background: High-risk multiple myeloma (MM) remains a major unmet clinical need despite BCMA-directed immunotherapy. We previously identified CD70 as enriched in adverse cytogenetic subgroups, including t(4;14), gain 1q, and loss 1p, and associated with inferior overall survival (Kasap et al, Blood 2025). We also developed a CD27-based natural-ligand CAR-T platform with superior in vivo expansion versus scFv-based CARs. Here, we examined whether CD70 contributes to aggressive myeloma biology beyond adverse cytogenetics and optimized CD70-targeted CAR-T therapy through computational binder engineering, signaling-domain selection, and scalable virus-free manufacturing.

Methods: CoMMpass IA19 RNA-seq and clinical data were analyzed using multivariable Cox modeling to test whether CD70 predicted overall survival independently of established high-risk cytogenetic features. Bulk RNA-seq compared t(4;14)-positive LP1 CD70-knockout cells with isogenic controls. We developed an N88A computationally optimized CD27 natural-ligand CAR to enhance CD70 binding. Virus-free CAR-T cells were generated by CRISPR-mediated TRAC knock-in using Cas9 RNPs with ssDNA or dsDNA donors, or transient Cas9 mRNA with dsDNA nanoplasmid donors, with concurrent CD70 knockout to reduce fratricide, followed by G-Rex expansion using an institutional GMP-adapted workflow. CD28ζ, 4-1BBζ, and 1XX signaling domains were compared by proliferation, cytokine profiling, bulk RNA-seq, longitudinal blood monitoring, tissue persistence, and LP1 xenograft studies.

Results: CD70 remained independently associated with inferior overall survival after adjustment for established high-risk cytogenetic features (HR 1.16, 95% CI 1.07–1.26; P<0.001), demonstrating prognostic value beyond genomic risk. CD70 knockout in LP1 cells induced 536 differentially expressed genes, including reduced SLAMF7 and IL21R expression and disruption of amino acid transport, serine/one-carbon metabolism, and adaptive stress-response pathways, supporting a tumor-intrinsic role for CD70 in aggressive MM.

Together, these findings established CD70 as a clinically relevant biomarker and a therapeutic target, supporting optimization of CD70-directed CAR-T therapy. We incorporated the computationally optimized N88A CD27 binder (Kang et al, ASGCT, Annual Meeting, 2025) into CARs containing CD28ζ, 4-1BBζ, or 1XX signaling domains. N88A CARs mediated potent antimyeloma activity across all three backbones in vitro. In an LP1 t(4;14) xenograft model, all constructs achieved durable tumor control through day 57 after infusion of only 100,000 CAR-T cells, whereas negative controls rapidly progressed. In a separate 1XX dose-titration study, all doses, including 50,000 CAR-T cells, eradicated established tumors and rejected tumor rechallenge. 1XX CAR-T cells expanded more than negative and 4-1BBζ controls, persisted in blood through day 42, and were enriched in bone marrow and spleen at study endpoint. Compared with CD28ζ, 1XX CAR-T cells showed sustained proliferation, preserved central-memory populations, restrained inflammatory cytokine production, and enrichment of memory, proliferation, and anti-apoptotic transcriptional programs, establishing 1XX as the lead construct.

To simplify virus-free manufacturing, dsDNA nanoplasmid donors supported TRAC-targeted CAR knock-in with concurrent CD70/TRAC double knockout and demonstrated a dose-dependent tradeoff between editing efficiency and cellular fitness using Cas9 RNPs. Peak TRAC-targeted CAR knock-in reached 20.6%–24.2% at 31.6 nM, whereas intermediate concentrations preserved substantially greater viability and expansion, establishing an optimal donor range for efficient virus-free CAR-T engineering. Using transient Cas9 mRNA with 20–40 nM nanoplasmid donors further increased TRAC-targeted CAR knock-in to 48.0%–51.2%, while maintaining high concurrent CD70 knockout efficiency comparable to that obtained with Cas9 RNPs.

Conclusions: CD70 is an independent adverse prognostic marker and a compelling therapeutic target in high-risk MM. Computationally optimized N88A 1XX CAR-T cells demonstrated superior expansion, persistence, and functional durability, identifying the lead platform for CD70-directed therapy. Finally, combining transient Cas9 mRNA with dsDNA nanoplasmid donors established an efficient, fully transient virus-free manufacturing strategy, providing a path toward a simplified, scalable, and clinically translatable nonviral CAR-T platform.

Bonell Patino-Escobar, MD: No relevant conflicts of interest to declare.